Skip to main content Accessibility help
×
Home
Hostname: page-component-544b6db54f-d2wc8 Total loading time: 1.379 Render date: 2021-10-25T07:46:38.079Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Book contents

Chapter 5 - Treatment of cervical dystonia

Published online by Cambridge University Press:  05 February 2014

Daniel Truong
Affiliation:
The Parkinson’s and Movement Disorders Institute, Fountain Valley, California
Karen Frei
Affiliation:
The Parkinson and Movement Disorder Institute, Orange Coast Memorial Center, Fountain Valley, CA, USA
Cynthia L. Comella
Affiliation:
Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA
Daniel Truong
Affiliation:
The Parkinson’s and Movement Disorders Institute, Fountain Valley, California
Dirk Dressler
Affiliation:
Department of Neurology, Hannover University Medical School
Mark Hallett
Affiliation:
George Washington University School of Medicine and Health Sciences, Washington, DC
Christopher Zachary
Affiliation:
Department of Dermatology, University of California, Irvine
Get access

Summary

Introduction

Cervical dystonia (CD), originally known as spasmodic torticollis and first described by Foltz in 1959, is a neurological syndrome characterized by abnormal head and neck posture caused by tonic involuntary contractions in a set of cervical muscles. However, CD and spasmodic torticollis are not interchangeable: CD is the preferred term when referring to idiopathic focal dystonia of the neck. Spasmodic torticollis is now considered to be one of four types of CD. Cervical dystonia is classified into four types based on the principal direction of head posture:

  • torticollis: abnormal rotation of the head to the right or to the left in the transverse plane

  • laterocollis: the head tilts toward the right or left shoulder

  • antecollis: the head pulls forward with neck flexion

  • retrocollis: the head pulls back with the neck hyperextended.

Cervical dystonia is slightly more common in females, with a male to female ratio of 1:1.2 (Kessler et al., 1999). Onset is usually insidious, although in some patients the onset has been reported as sudden. Cervical dystonia may develop in patients of all age groups, but the peak age of onset is 41 years (Kessler et al., 1999). Idiopathic CD usually progresses in severity over the first 5 years until it reaches a plateau, after which it remains fairly constant and becomes a lifelong condition. Although remission can occur, it is rare and the dystonia usually returns after a period of time. The cervical component may also exist as part of a more extensive form of dystonia, in which the dystonia can spread to involve adjacent structures such as the face or the arm(s). When dystonia involves several contiguous body parts, it is considered segmental dystonia. When it involves several parts of the body that are not contiguous, such as the neck and foot, it is called multifocal, and when it involves the majority of the body, it is referred to as generalized dystonia.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Benecke, R (1993). Botulinum-Toxin A in der Behandlung der zervikalen Dystonien. In Richter, HP, Braun, V (eds.) Schiefhals. Behandlungskonzepte des Torticollis Spasmodicus. Berlin: Springer, pp. 63–78.Google Scholar
Benecke, R (1999). Zervikale Dystonie. In Laskawi, R, Roggenkaemper, P (eds.) Botulinum-Toxin-Therapie im Kopf-Hals-Bereich. Munich: Urban & Vogel, pp. 171–212.Google Scholar
Benecke, R, Jost, WH, Kanovsky, MD et al. (2005). A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology, 64, 1949–51.CrossRefGoogle ScholarPubMed
Bertrand, CM (1993). Selective peripheral denervation for spasmodic torticollis: surgical technique, results, and observations in 260 cases. Surg Neurol, 40, 96–103.CrossRefGoogle ScholarPubMed
Blackie, JD, Lees, AJ (1990). Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry, 53, 640–3.CrossRefGoogle ScholarPubMed
Borodic, GE, Pearce, LB, Smith, K, Joseph, M (1992). Botulinum A toxin for spasmodic torticollis: multiple vs single injection points per muscle. Head Neck, 14, 33–7.CrossRefGoogle ScholarPubMed
Brashear, A, Lew, MF, Dykstra, DD et al. (1999). Safety and efficacy of NeuroBloc® (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology, 53, 1439–46.CrossRefGoogle Scholar
Brin, MF, Lew, MF, Adler, MD et al. (1999). Safety and efficacy of NeuroBloc® (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology, 53, 1431–8.CrossRefGoogle Scholar
Comella, CL, Buchmann, AS, Tanner, CM, Brown-Toms, NC, Goetz, CG (1992). Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology, 42, 878–82.CrossRefGoogle ScholarPubMed
Comella, CL, Jankovic, J, Truong, DD, Hanschmann, A, Grafe, S (2011). Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci, 308, 103–9.CrossRefGoogle ScholarPubMed
Davis, DH, Ahlskog, JE, Litchy, WJ, Root, LM (1991). Selective peripheral denervation for torticollis: preliminary results. Mayo Clin Proc, 66, 365–71.CrossRefGoogle ScholarPubMed
Foltz, EL, Knopp, LM, Ward, AA (1959). Experimental spasmodic torticollis. J Neurosurg, 16, 55–72.CrossRefGoogle ScholarPubMed
Frei, K, Pathak, M, Jenkens, S, Truong, DD (2004). The natural history of posttraumatic cervical dystonia. Mov Disord, 12, 1492–8.CrossRefGoogle Scholar
Gelb, DJ, Lowenstein, DH, Aminoff, MJ (1989). Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis. Neurology, 39, 80–4.CrossRefGoogle ScholarPubMed
Gelb, DJ, Yoshimura, DM, Olney, RK, Lowenstein, DH, Aminoff, MJ (1991). Change in pattern of muscle activity following botulinum toxin injections for torticollis. Ann Neurol, 29, 370–6.CrossRefGoogle ScholarPubMed
Greene, P, Kang, U, Fahn, S et al. (1990). Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology, 40, 1213–18.CrossRefGoogle ScholarPubMed
Hambleton, P, Cohen, HE, Palmer, VJ, Melling, J (1992). Antitoxins and botulinum toxin treatment. BMJ, 304, 959–60.CrossRefGoogle ScholarPubMed
Hatheway, CL, Dang, C (1994). Immunogenicity of the neurotoxins of Clostridium botulinum. In Jankovic, J, Hallett, M (eds.) Therapy with Botulinum Toxin. New York: Dekker, p. 107.Google Scholar
Jankovic, J, Brin, MF (1991). Therapeutic uses of botulinum toxin. N Engl J Med, 324, 1186–94.Google ScholarPubMed
Jankovic, J, Schwartz, PA (1990). Botulinum toxin injections for cervical dystonia. Neurology, 40, 277–80.CrossRefGoogle ScholarPubMed
Kessler, KR, Skutta, M, Benecke, R (1999). Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. J Neurol, 246, 265–74.CrossRefGoogle ScholarPubMed
Lew, MF, Adornato, BT, Duane, DD et al. (1997). Botulinum toxin type B. A double blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology, 49, 701–7.CrossRefGoogle ScholarPubMed
Lorentz, IT, Subramaniam, SS, Yiannikas, C (1991). Treatment of idiopathic spasmodic torticollis with botulinum toxin A: a double-blind study on twenty-three patients. Mov Disord, 6, 145–50.CrossRefGoogle ScholarPubMed
Moore, AP, Blumhardt, LD (1991). A double blind trial of botulinum toxin “A” in torticollis, with one year follow up. J Neurol Neurosurg Psychiatry, 54, 813–16.CrossRefGoogle Scholar
Naumann, M, Yakovleff, A, Durif, F (2002). A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin and current bold toxin source for the treatment of cervical dystonia. J Neurol, 249, 57–63.CrossRefGoogle Scholar
Poewe, W, Schelosky, L, Kleedorfer, B et al. (1992). Treatment of spasmodic torticollis with local injections of botulinum toxin. One-year follow-up in thirty-seven patients. J Neurol, 239, 21–5.CrossRefGoogle Scholar
Stell, R, Bronstein, AM, Marsden, CD (1989). Vestibulo-ocular abnormalities in spasmodic torticollis before and after botulinum toxin injections. J Neurol Neurosurg Psychiatry, 52, 57–62.CrossRefGoogle ScholarPubMed
Truong, D, Lewitt, P, Cullis, P (1989). Effects of different injection techniques in the treatment of torticollis with botulinum toxin. Neurology, 39(Suppl), 294.Google Scholar
Truong, D, Dubinski, R, Hermanowicz, N et al. (1991). Posttraumatic torticollis. Arch Neurol, 48, 221–3.CrossRefGoogle ScholarPubMed
Truong, D, Duane, DD, Jankovic, J et al. (2005). Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 20, 783–91.CrossRefGoogle ScholarPubMed
Truong, D, Brodsky, M, Lew, M et al. for the Global Dysport Cervical Dystonia Study Group (2010). Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord, 16, 316–23.CrossRefGoogle Scholar
Tsui, JK, Eisen, A, Mak, E et al. (1985). A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci, 12, 314–16.CrossRefGoogle ScholarPubMed
Tsui, JK, Eisen, A, Stoesl, AJ, Calne, S, Calne, DB (1986). Double-blind study of botulinum toxin in spasmodic torticollis. Lancet, ii, 245–7.CrossRefGoogle Scholar
Wissel, J, Poewe, W (1992). Dystonia: a clinical, neuropathological and therapeutic review. J Neural Transm Suppl, 38, 91–104.Google ScholarPubMed
Van Zandijcke, M (1995). Cervical dystonia (spasmodic torticollis). Some aspects of the natural history. Acta Neurol Belg, 95, 210–15.Google ScholarPubMed
2
Cited by

Send book to Kindle

To send this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Send book to Dropbox

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Dropbox.

Available formats
×

Send book to Google Drive

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Google Drive.

Available formats
×